Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein

Human Gene Therapy
F L HallW F Anderson

Abstract

Targeted gene delivery to vascular lesions is a major challenge in the development of gene therapy protocols for cardiovascular diseases. One approach would be to enable retroviral vectors to accumulate at sites of vascular injury and enhance local vector concentration. An early step in wound repair is the adhesion of platelets to collagen exposed from damaged vasculature. Hence, the Moloney murine leukemia virus (MoMLV) envelope (env) protein was engineered to incorporate a high-affinity collagen-binding domain derived from von Willebrand clotting factor, and expressed in Escherichia coli and in mammalian cells. The chimeric env protein bound tightly to collagen, and virions bearing this collagen-binding env protein exhibited viral titers approaching those of virions expressing wild-type (WT) env protein. The chimeric virions were concentrated on collagen matrices, and they retained their infectivity under conditions in which virions bearing WT env protein were washed away. Targeted delivery of the chimeric env protein to injured mouse aorta and selective binding of the collagen-targeted virions to injured rabbit artery were observed. In comparative studies, vascular smooth muscle cell transduction was demonstrated in catheter...Continue Reading

References

Sep 1, 1991·Circulation·J J PopmaE J Topol
Jan 1, 1990·Annual Review of Cell Biology·D D Wagner
Aug 1, 1995·Proceedings of the National Academy of Sciences of the United States of America·N V SomiaI M Verma
Dec 1, 1994·Current Opinion in Biotechnology·E M Gordon, W F Anderson
Jan 1, 1995·Fundamental & Clinical Pharmacology·L J FeldmanP G Steg
Jan 15, 1995·Circulation·E G Nabel
May 19, 1994·The New England Journal of Medicine·G H Gibbons, V J Dzau
Mar 11, 1993·Nucleic Acids Research·S J RussellG Winter
Apr 1, 1993·Human Gene Therapy·B Salmons, W H Günzburg
Aug 1, 1996·Cardiovascular Research·L J FeldmanG Steg
Jan 1, 1996·Connective Tissue Research·T L TuanF L Hall

❮ Previous
Next ❯

Citations

Mar 30, 2000·The Journal of Gene Medicine·S J Russell, F L Cosset
Oct 18, 2001·Current Opinion in Biotechnology·D LavilletteF L Cosset
Oct 6, 1999·Current Opinion in Biotechnology·K W Peng, S J Russell
Sep 28, 1999·Molecular Medicine Today·K W Peng
Jul 7, 2001·Human Gene Therapy·E M GordonF L Hall
Oct 24, 2000·Journal of Virology·S SharmaT Friedmann
Dec 21, 2012·Future Microbiology·Peter M Mazari, Monica J Roth
Jun 22, 2007·Proceedings of the National Academy of Sciences of the United States of America·Anindita SarangiMonica J Roth
Sep 12, 2000·Current Cardiology Reports·J F DedieuD Branellec
Apr 14, 2010·Expert Opinion on Biological Therapy·Erlinda M Gordon, Frederick L Hall
Jan 8, 1999·Journal of Molecular Biology·M P ChadwickS J Russell
Jan 27, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ghiabe H GuibingaTheodore Friedmann
Jun 17, 1999·Alcoholism, Clinical and Experimental Research·C Di CampliM A Zern
Jan 7, 2003·Nature Medicine·Thomas J Wickham
Oct 9, 2002·Oncogene·Renae L MalekNorman H Lee
Jan 1, 2009·Molecular Genetics, Microbiology and Virology : Molekulyarnaya Genetika, Mikrobiologiya I Virusologiya·E D Sverdlov
Apr 26, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·C HughesD Darling

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.